Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCalvete, Julio
dc.contributor.authorTaylor-Stokes, Gavin
dc.contributor.authorÁlvarez Ayerza, Néstor
dc.contributor.authorVilanova Larena, David
dc.contributor.authorManley Daumont, Melinda
dc.contributor.authorcedres, susana
dc.date.accessioned2025-03-07T11:26:27Z
dc.date.available2025-03-07T11:26:27Z
dc.date.copyright2024
dc.date.issued2025-01
dc.identifier.citationCedres S, Calvete J, Taylor-Stokes G, Álvarez Ayerza N, Vilanova Larena D, Daumont M. Treatment patterns and humanistic burden of malignant pleural mesothelioma in Spain. Clin Transl Oncol. 2025 Jan;27:213–22.
dc.identifier.issn1699-3055
dc.identifier.urihttp://hdl.handle.net/11351/12712
dc.descriptionHealth-related quality of life; Malignant pleural mesothelioma; Treatment
dc.description.abstractPurpose Malignant pleural mesothelioma (MPM) is an aggressive cancer with long latency and poor prognosis. The real-world treatment patterns and humanistic burden of MPM in an international cohort of patients were recently published. Spanish data are currently lacking and are reported here. Methods/Patients Data were collected from three sources: physician-abstracted demographic, clinical and treatment characteristics of patients with MPM; patient-completed questionnaires on treatment satisfaction, symptoms, caregiver use, and impact of the disease; and caregiver-completed questionnaire reporting their activity and its impact on their daily life. Results The 241 patients in Spain were primarily elderly (median age: 67 years), male, retired/unemployed/on long-term sick leave, and diagnosed at stage IV with unresectable disease. Exposure to asbestos was detected (54%, 101/188). First-line treatment (1L) consisted primarily of doublet chemotherapy (86%, 207/241). Of 102 patients who completed 1L at data abstraction, 67 were receiving maintenance therapy, most commonly singlet chemotherapy with pemetrexed. Best supportive care was given to 29 patients, primarily after 1L (86.2%, 25/29). Symptom burden was high and health-related quality of life was poor and declined with progression: mean (SD) EQ-5D score and EQ-5D visual analogue scale score were 0.615 (0.285) and 60.8 (17.1) in 1L and 0.497 (0.370) and 56.1 (19.5) in second line. Overall, 67% of patients (162/241) required daily assistance from their caregiver, who reported an impact on their psychological well-being. Conclusions Patients with MPM in Spain were overall treated according to treatment guidelines at the time. Nevertheless, a considerable burden of disease was reported by patients and caregivers.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesClinical and Translational Oncology;27
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectQüestionaris
dc.subjectPleura - Càncer - Tractament
dc.subjectMesotelioma - Tractament
dc.subjectPacients - Satisfacció
dc.subjectAssistència sanitària - Cost
dc.subject.meshPleural Neoplasms
dc.subject.meshMesothelioma
dc.subject.mesh/drug therapy
dc.subject.meshQuality of Life
dc.subject.meshSurveys and Questionnaires
dc.subject.meshCost of Illness
dc.titleTreatment patterns and humanistic burden of malignant pleural mesothelioma in Spain
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s12094-024-03591-5
dc.subject.decsneoplasias pleurales
dc.subject.decsmesotelioma
dc.subject.decs/farmacoterapia
dc.subject.decscalidad de vida
dc.subject.decsencuestas y cuestionarios
dc.subject.decscoste de las enfermedades
dc.relation.publishversionhttps://doi.org/10.1007/s12094-024-03591-5
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Cedres S] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Calvete J] Hospital Universitario Puerta del Mar, Cádiz, Spain. [Taylor Stokes G] Adelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfeld, Cheshire, UK. [Álvarez Ayerza N, Vilanova Larena D] Bristol Myers Squibb, Madrid, Spain. [Daumont M] Bristol Myers Squibb, Braine L’Alleud, Belgium
dc.identifier.pmid38970770
dc.identifier.wos001263434500002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record